Table 1 Primers that were used in this study
From: The immunogenicity of PRV ΔgE/TK/UL49.5 three-gene-deleted vaccine in mice
Primer | Sequence (5′ → 3′) | Restriction site | Expected product (bp) |
|---|---|---|---|
UL49.5L-F | CGGGGTACCAGGCGGAGGAAGACGAGGCT | Kpn I | 960 |
UL49.5L-R | CCCAAGCTTATAACTTCGTATAATGTATGCTATACGAAGTTATGTCGCACCACCAACGGGAT | Hind III | |
UL49.5R-F | CCGGAATTCATAACTTCGTATAGCATACATTATACGAAGTTATTTCCCACTCGCTCGCCATGT | EcoR I | 896 |
UL49.5R-R | CGCACTAGTGAACGCGACCACGCACTCC | Spe I | |
EGFP-F | CCCAAGCTTGGGACTTTCCATTGACG | Hind III | 1452 |
EGFP-R | CCGGAATTCAATTTACGCGTTAAGATAC | EcoR I | |
UL49.5-F | GATGTCGTATCCGGCGTC | – | 853 |
UL49.5-R | TCGTAGGACGGGGCAGAC | – | |
SLA-I-qF | CTTCCACTCGCAGCTCTTCT | – | 113 |
SLA-I-qR | TAGATGCAGGGCTCGTACAC | – | |
β-actin qF | TCCTGCGGCATCCACGAAAC | – | 82 |
β-actin qR | CCGTGTTGGCGTAGAGGTCCTTG | – |